- Home
- UFCS vs PHAR Comparison
UFCS vs PHAR Comparison
Compare UFCS & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UFCS | PHAR |
|---|---|---|
| Founded | 1946 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 933.8M | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UFCS | PHAR |
|---|---|---|
| Price | $37.09 | $17.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $37.50 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 144.9K | 23.0K |
| Earning Date | 02-10-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | ★ 118.04 | N/A |
| EPS | ★ 4.24 | 0.00 |
| Revenue | ★ $1,353,781,000.00 | $362,274,000.00 |
| Revenue This Year | $10.11 | $25.19 |
| Revenue Next Year | $3.33 | $4.47 |
| P/E Ratio | ★ $8.79 | $3,089.47 |
| Revenue Growth | 12.12 | ★ 26.78 |
| 52 Week Low | $24.11 | $7.50 |
| 52 Week High | $37.91 | $18.12 |
Technical Indicators
Market Signals| Indicator | UFCS | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 60.12 | 54.31 |
| Support Level | $36.46 | $16.15 |
| Resistance Level | $37.91 | $17.00 |
| Average True Range (ATR) | 0.88 | 0.76 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 82.06 | 53.81 |
Price Performance
Historical ComparisonAbout UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.